Your Feed

Filter by
See content from
Back to the latest
Avatar
Dave P
Multiple Myeloma Discussion • December 12, 2023
Progression on Dara/Pom - What's Next?
AI-generated title
Anyone else have this?: There is a monoclonal protein present overlying transferrin in the beta region that measures between 0.8 and 1.3 g/dl with suppression of polyclonal immunoglobulins. Immunofixation electrophoresis is consistent with the previously identified IgA kappa monoclonal gammopathy. The monoclonal protein cannot be accurately measured with this methodology. IFE also shows a small free kappa monoclonal protein (monoclonal protein #2) in the alpha-2 region. I ask my Dr and am just told the disease is "progressing"?? Since for 10 yrs I've watched the mspike, now not sure how well the meds are working since light chains are very high. Am on dara faspro and Pom this year and not seeing results but have to keep stopping the Pom due to low blood cells...Keep reading about other new meds like Ventaclave, etc?? My beta 2 is very high and i wonder what can bring that down? Thanks and happy holidays.
Avatar
SetyBlue
Multiple Myeloma Discussion • December 12, 2023
Experiencing Tingling and Weakness From Bactrim?
AI-generated title
I have been put on Bactrim (sulfamemethoxazole and trimethoprim) anti bacterial pills after ASCT. I am taking this drug three times a week, on Mondays, Wednesdays and Fridays. I am supposed to be on it for at least two months but I think I am getting weird side effects from it. I’ve been on it for a month now, and I have noticed that by Friday there’s tingling in my hands and feet, and I think I am getting some muscle weakness and slight dizziness as well. After being off it for Saturday and Sunday, some of the side effects are lessened, but then get worse by Friday. Has anyone experienced this with this drug?
Avatar
grayDolphin
Multiple Myeloma Discussion • December 12, 2023
Interpreting Pre-SCT Biopsy Results?
AI-generated title
Can someone interpret these results of husbands pre-stem cell bone marrow biopsy that was completed post RVD therapy (SCT is next week) Thanks! FINAL DIAGNOSIS A-D. Bone marrow, right iliac crest, aspirate with clot preparation and biopsy with touch imprints, and peripheral blood smear: 1. Monotypic lambda light chain restricted, hyperdiploid, plasma cells, 3% by morphologic differential. 2. Normocellular bone marrow for age (25%) with unremarkable background trilineage hematopoiesis.
Thumbnail for Addressing Racial and Ethnic Disparities in AML Clinical Trials | Andrew Hantel, MD | ASH 2023
Playlist: ASH 2023

Addressing Racial and Ethnic Disparities in AML Clinical Trials | Andrew Hantel, MD | ASH 2023

Video details & playlist
Thumbnail for Study on Minimizing Exclusion for AML Patients in Clinical Trials | Andrew Hantel, MD | ASH 2023
Playlist: ASH 2023

Study on Minimizing Exclusion for AML Patients in Clinical Trials | Andrew Hantel, MD | ASH 2023

Video details & playlist
Thumbnail for Results from Venetoclax Added to CLAD Combo for Older Patients With AML | Tapan Kadia, MD | ASH 2023
Playlist: ASH 2023

Results from Venetoclax Added to CLAD Combo for Older Patients With AML | Tapan Kadia, MD | ASH 2023

Video details & playlist
Thumbnail for Moving to a Fully Oral Drug Combination for Older/Frail AML Patients | Tapan Kadia, MD | ASH 2023
Playlist: ASH 2023

Moving to a Fully Oral Drug Combination for Older/Frail AML Patients | Tapan Kadia, MD | ASH 2023

Video details & playlist
Thumbnail for Extending AML Remissions with Hypomethylating Agents and Venetoclax | Tapan Kadia, MD | ASH 2023
Playlist: ASH 2023

Extending AML Remissions with Hypomethylating Agents and Venetoclax | Tapan Kadia, MD | ASH 2023

Video details & playlist
Thumbnail for Real World Teclistamab Results for Relapsed Refractory Myeloma Patients | Meera Mohan, MD | ASH 2023
Playlist: ASH 2023

Real World Teclistamab Results for Relapsed Refractory Myeloma Patients | Meera Mohan, MD | ASH 2023

Video details & playlist
Thumbnail for Updates to Management of CAR-T and Teclistamab for Myeloma Patients | Radhika Bansal, MD | ASH 2023
Playlist: ASH 2023

Updates to Management of CAR-T and Teclistamab for Myeloma Patients | Radhika Bansal, MD | ASH 2023

Video details & playlist
Thumbnail for Impact of Financial Toxicity and Time Toxicity in Myeloma QOL | Rahul Banerjee, MD, FACP | ASH 2023
Playlist: ASH 2023

Impact of Financial Toxicity and Time Toxicity in Myeloma QOL | Rahul Banerjee, MD, FACP | ASH 2023

Video details & playlist
Thumbnail for Real-World Bortezomib Patterns in Newly Diagnosed Myeloma | Gurbakhash Kaur, MD, MA | ASH 2023
Playlist: ASH 2023

Real-World Bortezomib Patterns in Newly Diagnosed Myeloma | Gurbakhash Kaur, MD, MA | ASH 2023

Video details & playlist
Thumbnail for Fine Particulate Matter and Myeloma Outcomes in Urban Cohort | Michael Wysota, MD | ASH 2023
Playlist: ASH 2023

Fine Particulate Matter and Myeloma Outcomes in Urban Cohort | Michael Wysota, MD | ASH 2023

Video details & playlist
Thumbnail for Genomic Profiling in High-Risk Smoldering Myeloma | Benjamin Diamond, MD | ASH 2023
Playlist: ASH 2023

Genomic Profiling in High-Risk Smoldering Myeloma | Benjamin Diamond, MD | ASH 2023

Video details & playlist
Thumbnail for Dexamethasone Dose Strength Impact in Newly Diagnosed Myeloma | Rahul Banerjee, MD, FACP | ASH 2023
Playlist: ASH 2023

Dexamethasone Dose Strength Impact in Newly Diagnosed Myeloma | Rahul Banerjee, MD, FACP | ASH 2023

Video details & playlist
Thumbnail for CAR-T in Myeloma Patients with Extramedullary and Paramedullary Disease | Darren Pan, MD | ASH 2023
Playlist: ASH 2023

CAR-T in Myeloma Patients with Extramedullary and Paramedullary Disease | Darren Pan, MD | ASH 2023

Video details & playlist
Thumbnail for Real-World Patient Profile and Dosing of Teclistamab in Myeloma | Carlyn Rose Tan, MD | ASH 2023
Playlist: ASH 2023

Real-World Patient Profile and Dosing of Teclistamab in Myeloma | Carlyn Rose Tan, MD | ASH 2023

Video details & playlist